Disorders In HIV-infected Patients Research Articles

Assessment of neurocognitive disorders in HIV infected patients receiving combination of anti-retroviral therapy at a tertiary care hospital - An observational study

cARTTherapy (combination antiretroviral therapy) has improved the live expectancy of people living with HIV (PLHIV). But HIV associated neurocognitive disorders (HAND) are still prevalent. One of the factors associated could be the cARTtherapy itself. The study aims to calculate the prevalence of HAND and associated risk factors in PLHIV who are on Cart therapy and to compare the efficiency of MMSE and IHDS scales in the assessment of HAND. A case-control study involving 54 PLHIV on cART therapy and 27 HIV negative controls were screened for their neurocognition by two neuropsychological tests such as MMSE and IHDS, followed by staging into Asymptomatic Neurological Impairment (ANI), Mild Neurocognitive Impairment (MND), HIV Associated Dementia (HAD) in PLHIV. Statistical analysis was done using suitable software. The overall prevalence of HAND in our study was found to be 70.37%. Prevalence estimates for specific HAND diagnoses were 57.89% ANI, 28.9% MND, and 13.1 % HAD. IHDS demonstrated good screening ability for HAND with an optimal cut-off score of 10, high sensitivity of 70% and minimal specificity. Age, male gender, low literacy, presence of comorbidities, severity of the disease, cART regimen with low CPE (CNS penetration effectiveness) score were strongly correlated. Study findings suggest that IHDS serves as a better screening tool for HAND with greater sensitivity and can facilitate further cognitive evaluation. The overall prevalence was found to be equivalent to that of the recently reported studies.

Coagulation Parameters in Human Immunodeficiency Virus Infected Patients: A Systematic Review and Meta-Analysis

Background Coagulation abnormalities are common complications of human immunodeficiency virus (HIV) infection. Highly active antiretroviral treatment (HAART) decreased the mortality of HIV but increased coagulopathies. HIV-related thrombocytopenia, prolonged prothrombin time (PT), activated partial thromboplastin time (APTT), and high D-dimer level commonly manifested in patients with HIV. Thus, this study is aimed to compare coagulation parameters of HAART-treated and HAART-naïve HIV-infected patients with HIV-seronegative controls. Methods A systematic literature search was conducted using the databases PubMed/MEDLINE, Embase, Web of Science, and Google Scholar of studies published until July 2021. The primary outcome of interest was determining the pooled mean difference of coagulation parameters between HIV-infected patients and seronegative controls. The Joana Briggs Institute (JBI) critical appraisal tool was used for quality appraisal. Statistical analyses were performed using Stata11.0 software. The statistical results were expressed as the effect measured by standardized mean difference (SMD) with their related 95% confidence interval (CI). Results A total of 7,498 participants (1,144 HAART-naïve patients and 2,270 HAART-treated HIV-infected patients and 3,584 HIV-seronegative controls) from 18 studies were included. HIV-infected patients (both on HAART and HAART-naive) exhibited significantly higher levels of PT than HIV-seronegative controls (SMD = 0.66; 95% CI: 0.53–0.80 and SMD = 1.13; 95% CI: 0.60–2.0, respectively). The value of APTT was significantly higher in patients with HIV on HAART than in seronegative controls. However, the values of PLT count, APTT, and fibrinogen level were significantly higher in seronegative controls. Besides, the level of fibrinogen was significantly higher in HAART-treated than treatment-naïve patients (SMD = 0.32; 95%CI: 0.08, 0.57). Moreover, the level of APTT and PT had no statistical difference between HAART and HAART-naïve HIV-infected patients. Conclusions This study identified that HIV-infected patients are more likely to develop coagulation abnormalities than HIV-seronegative controls. Therefore, coagulation parameters should be assessed regularly to prevent and monitor coagulation disorders in HIV-infected patients.

Evaluation of lipid metabolism imbalance in HIV-infected patients with metabolic disorders using high-performance liquid chromatography-tandem mass spectrometry

Human immunodeficiency virus (HIV) infection and highly active antiretroviral therapy use are associated with the disruption of lipid and glucose metabolism. Herein, a sensitive and robust high-performance liquid chromatography–tandem mass spectrometry method for the quantitation of lysophosphatidylcholines (LPCs) and acylcarnitines (ACs) in human blood serum was developed and validated to investigate them as markers of metabolic disorders in HIV-infected patients. Under optimal extraction and detection conditions, the lower limits of quantification reached 5 ng/mL (LPCs) and 0.1 ng/mL (ACs), and precision and accuracy for both intra- and inter-day analyses were generally below 15%. Serum samples were stable for at least six months when stored at − 80 °C and for at least 12 h when stored at 4 °C or 25 °C. We investigated inter-group differences and associations between the biomarkers and observed a particular volatilitytrend of LPCs and ACs for HIV-infected patients with metabolic disorders. Thus, the developed method can be used for the rapid and sensitive quantitation of LPCs and ACs in vivo to further appraise the process of HIV infection, evaluate interveningmeasures, conduct mechanistic investigations, and further study the utility of LPCs and ACs as biomarkers of HIV infection coupled with metabolic disorders.

Neuropsychiatric Adverse Events During 12 Months of Treatment With Efavirenz in Treatment-Naïve HIV-Infected Patients in China: A Prospective Cohort Study.

Background: Efavirenz (EFV) is widely used in antiretroviral therapy (ART), but the incidence and risk factors of neuropsychiatric adverse events (NPAEs) after EFV treatment have rarely been studied in Chinese ART naïve patients.Methods: This prospective cohort study assessed HIV-infected patients initiating antiretroviral treatment with EFV to determine prevalence of and factors associated with NPAEs over a 12-month follow-up period using the Hospital Anxiety and Depression Scale (HADS) and the Pittsburgh Sleep Quality Index (PSQI).Results: A total of 546 patients were enrolled. Prevalence of anxiety, depression, and sleep disturbances at baseline were 30.4, 22.7, and 68.1%, respectively. Six patients discontinued treatment due to drug related NPAEs. Treatment was associated with improvements in HADS-A, HADS-D, and PSQI scores over the 12-month follow-up, and the frequencies of patients with anxiety, depression, and sleep disturbances significantly decreased after 12 months. Abnormal baseline HADS-A, HADS-D, and PSQI scores and other factors, including high school education or lower income, unemployment, divorce, and WHO III/IV stages, were associated with severe neuropsychiatric disorders over the 12 months.Conclusions: These findings suggested EFV discontinuation due to NAPEs was low, and the HADS-A, HADS-D, and PSQI scores after 12 months of EFV treatment were associated with several risk factors. The clinicians should keep in mind and routinely screen for the risk factors associated with neuropsychiatric disorders in HIV-infected patients.

Vaginal Microbiocenosis Features in HIV-positive Women of Fertile Age

Aim and Objective of Our Study: The aim and objective of our study is to analyze the research data that has been studying the effect of HIV infection on vaginal microbiocenosis and further, to determine the differences in dysbiotic disorders in seronegative and seropositive women. We have also assessed the effect of vaginal microbiota on pre-exposure prophylaxis of HIV.
 Materials and Methods: Evaluation of the Russian and other countries results on the microbiota of HIV-positive women studies, published in international databases.
 Results: The analysis of the research data aimed at studying the effect of HIV infection on the vaginal microbiocenosis indicates that dysbiotic disorders in HIV-infected patients are significantly more frequent. It has been revealed that the atypical clinical picture of changes in the vaginal microbiocenosis prevails. It has been noted that there is a correlation of vaginal microbiocenosis in HIV-positive women and indicators of systemic immunity, CD4 + cell levels.
 Conclusion: Based on analysis of published in international databases Russian and other countries studies results on the HIV-positive women microbiota, it was found that there is a need for additional studies of the qualitative and quantitative composition of the microbiota of HIV-positive women. It is need to assess the of the vaginalmicrobiotaand other possible connected factors ability to change the concentration of antiretroviral drugs.

Epigenetic Suppression of HIV in Myeloid Cells by the BRD4-Selective Small Molecule Modulator ZL0580.

Brain-resident microglia and myeloid cells (perivascular macrophages) are important HIV reservoirs in vivo, especially in the central nervous system (CNS). Despite antiretroviral therapy (ART), low-level persistent HIV replication in these reservoirs remains detectable, which contributes to neuroinflammation and neurological disorders in HIV-infected patients. New approaches complementary to ART to repress residual HIV replication in CNS reservoirs are needed. Our group has recently identified a BRD4-selective small molecule modulator (ZL0580) that induces the epigenetic suppression of HIV. Here, we examined the effects of this compound on HIV in human myeloid cells. We found that ZL0580 induces potent and durable suppression of both induced and basal HIV transcription in microglial cells (HC69) and monocytic cell lines (U1 and OM10.1). Pretreatment of microglia with ZL0580 renders them more refractory to latent HIV reactivation, indicating an epigenetic reprogramming effect of ZL0580 on HIV long terminal repeat (LTR) in microglia. We also demonstrate that ZL0580 induces repressive effect on HIV in human primary monocyte-derived macrophages (MDMs) by promoting HIV suppression during ART treatment. Mechanistically, ZL0580 inhibits Tat transactivation in microglia by disrupting binding of Tat to CDK9, a process key to HIV transcription elongation. High-resolution micrococcal nuclease mapping showed that ZL0580 induces a repressive chromatin structure at the HIV LTR. Taken together, our data suggest that ZL0580 represents a potential approach that could be used in combination with ART to suppress residual HIV replication and/or latent HIV reactivation in CNS reservoirs, thereby reducing HIV-associated neuroinflammation.IMPORTANCE Brain-resident microglia and perivascular macrophages are important HIV reservoirs in the CNS. Persistent viral replication and latent HIV reactivation in the CNS, even under ART, are believed to occur, causing neuroinflammation and neurological disorders in HIV-infected patients. It is critical to identify new approaches that can control residual HIV replication and/or latent HIV reactivation in these reservoirs. We here report that the BRD4-selective small molecule modulator, ZL0580, induces potent and durable suppression of HIV in human microglial and monocytic cell lines. Using an in vitro HIV-infected, ART-treated MDM model, we show that ZL0580 also induces suppressive effect on HIV in human primary macrophages. The significance of our research is that it suggests a potential new approach that has utility in combination with ART to suppress residual HIV replication and/or HIV reactivation in CNS reservoirs, thereby reducing neuroinflammation and neurological disorders in HIV-infected individuals.

Glutamine and its derivatives in the correction of metabolic disorders in HIV-infected patients (review)

It has been established that HIV-infection is associated with progressive deficiency of L-glutamine followed by immune dysfunction, reduced body mass and muscle strength, morphological disorders and functional disintegration of the intestine, as well as neurological disorders. According to current ideas, correction of L-glutamine deficiency is one of the important components of adjuvant therapy for HIV-infected patients within general nutritional support strategy. This measure helps to slow development of AIDS, reduce side effects of antiretroviral therapy and enhance effectiveness.

Psychopathological symptoms and indicators of cellular immunity in HIV-infected patients with schizophrenia and schizoaffective disorder

The correlation between psychopathological disorders and indicators related to the effector molecule in cell-mediated immunity in HIV-infected patients with schizophrenia and schizoaffective disorder has been studied using comparison of means and regression analysis. HIV infection affects individual indicators of the effector molecule in cellular immunity in patients with paranoid schizophrenia and schizoaffective disorder, and its influence differs in schizophrenia and schizoaffective disorder and in various forms of schizophrenia. The structure of psychopathological disorders in HIV-infected patients with schizophrenia and schizoaffective disorder correlates with the immunoregulatory index CD4+/CD8+, which reflects the involvement of the effector of cell-mediated immunity in the formation of a clinical picture of psychopathological disorders.

New characteristics of neurophysiological changes in neurocognitive disorders in HIV-infected patients in Uzbekistan

We aim to study the features of electroencephalographic indices taking into account Р300 in the formation of early neurocognitive disorders. EEG registration was provided out in 20 patients (11 women and 9 men) at rest and with functional tests, the cognitive evoked potentials of the brain P300 upon presentation of visual and auditory stimuli, measured the time of complex sensory-motor responses upon presentation of visual and auditory stimuli, were recorded visual evoked potentials during pattern stimulation. The average age of patients was 35.2 ± 8.8 years. The number of CD4 lymphocytes in blood plasma ranged from 230 to 859 cells / μl, the average was 451 ± 55 cells/μl. Of the 18 patients in whom local changes on the EEG were recorded, involvement of the temporal areas was noted in 94% of cases, the frontal-central areas - in 66% of cases, parietal-occipital - in 50% of cases. When registering visual evoked potentials in 75% of cases, an increase in the latent period of the P300 component was observed on average from 10 to 30% with a decrease in the amplitude of the P300 component and signs of desynchronization of excitation in the visual cortex. For men, the average latent period of P100 was 117.9 ± 7.7 ms, for women - 111.2 ± 7.0 ms (normative data: 102.3 ± 3.2 ms). The obtained results indicate that the presence of diffuse changes, which were characterized mainly by local irritative and epileptiform changes, can serve as electrophysiological criteria for HIV infection.

Mitochondrial Haplogroups N9 and G Are Associated with Metabolic Syndrome Among Human Immunodeficiency Virus-Infected Patients in China.

Increasing evidence shows that mitochondrial DNA (mtDNA) variations have an important effect on metabolic disorders, but such studies have not been conducted in HIV-infected patients in Asia. We investigated the distribution of mtDNA haplogroups and their correlation with metabolic disorders in HIV-infected patients. A cross-sectional survey was performed among 296 HIV patients older than the age of 40 years in a rural prefecture, Eastern China. The entire mtDNA sequence was amplified by polymerase chain reaction using four overlapping pairs of primers that have been standardly used. In this sample, mtDNA haplogroups B, D, M7, and F were the most dominant haplogroups. The overall prevalence of metabolic syndrome (MetS) was 36.1%, and was highest (77.8%) among those with haplogroup G and lowest (21.4%) among those with haplogroup M8. In multivariable analysis, haplogroups G and N9 were significantly associated with the presence of MetS [adjusted odds ratio (aOR) = 13.5, 95% confidence interval (CI): 1.9-94.7; aOR = 8.1, 95% CI: 1.8-36.1; respectively]. Moreover, patients with haplogroup G had increased odds of elevated glycated hemoglobin (HbA1c) (aOR = 10.1, 95% CI: 1.4-71.1), patients with haplogroup N9 had increased odds of elevated triglycerides (aOR = 13.5, 95% CI: 2.4-76.8). No significant association between mtDNA haplogroups and other MetS components was observed. Our data demonstrate the association between mtDNA haplogroups and MetS in HIV-infected patients. The Asian-specific mtDNA haplogroups G and N9 may confer higher risk for the development of MetS in HIV-infected patients, which requires further longitudinal investigation.

Primary Headache Disorders in HIV-Infected Patients within a Hospital Setting in Sub-Saharan Africa, Benin Case: Prevalence and Associated Factors

Introduction: Headache disorders are common in HIV-infected patients. These disorders are either primary or secondary. Objective: Determine prevalence and factors associated with primary headache disorders in HIV+ patients. Method: It was a cross-sectional, descriptive and analytical study conducted from 2nd May 2017 to 2nd August 2017 which included HIV+ patients aged 18 years and above. Diagnosis of primary headache disorders was carried out by a Neurologist on the basis of ICHD-II diagnostic criteria. The dependent variable was primary headache disorders. Epi Info Version 7.2.1.0 and STATA11 were used for data analysis. P Results: Primary headache disorders prevalence was 25.2% (124/493).Tension-type headache represented 77.41%. HIV+ patients were aged 42.63 ± 10.14 years. Sex-ratio was estimated at 0.14. Factors associated with primary headache disorders in HIV+ patients were: male (0.36 [0.17 - 0.77]; P = 0.008), Dendi ethnicity (14.8 [2.08 - 101.99]; P = 0.007), trader (3.09 [01.25 - 7.62]; P = 0.02), WHO clinical stage (3.20 [1.43 - 7.17]; P = 0.005), screening duration (1.01 [1.00 - 1.01]; P = 0.00), hypertension (10.28 [4.44 - 23.83]; P ≤ 0.001). Conclusion: This study helped to determine the standard profile of HIV+ patient with primary headache disorders. It will contribute to save costs associated with paraclinical examinations, while in search of secondary etiologies within an African context with limited financial resources.

Diffuse connective tissue disorders in HIV-infected patients.

Background:Human immunodeficiency virus (HIV) infection has been associated with various autoimmune disorders.Aim:To review the spectrum of diffuse connective tissue disorders (dCTD) in HIV-infected patients, in the context of highly active anti-retroviral therapy.Methods:Electronic search of the literature was performed using the terms HIV, AIDS, autoimmune, rheumatic/rheumatological, immune reconstitution inflammatory syndrome, Systemic Lupus Erythematosus, Diffuse Infiltrative Lymphocytosis Syndrome, Sjogren’s syndrome, vasculitis, Behçet’s disease, cryoglobulins, Henoch-Schönlein purpura, and antiphospholipid syndrome.Results:We reviewed the clinical manifestations, natural history and treatment of dCTDs, since the implementation of Highly Active Anti-Retroviral Therapy (HAART), and the emergence of new pathogenic mechanisms, such as the immune reconstitution inflammatory syndrome.Conclusions:Caution in differentiating clinical and laboratory findings of dCTDs from non-specific manifestations of acute and chronic HIV infection is warranted due to the common presentation. Patients with chronic infection and access to HAART have a normal life expectancy and dCTDs, although rare, must be correctly addressed. HAART alone or combined with immunosuppressive therapy result in favourable outcomes.

Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial

BackgroundThe prevalence of bipolar disorder in HIV-infected patients is higher than the general population. Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used as part of combination antiretroviral therapy (ART). Both TDF and lithium are associated with renal tubular toxicity, which could be additive, or a pharmacokinetic interaction may occur at renal transporters with a decrease in TDF elimination.ObjectiveWe report on the change in estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease formula in participants who received ART including TDF and were enrolled in a 24 week randomised trial of lithium versus placebo in patients with HIV-associated neurocognitive impairment.MethodsWe included HIV-infected adults with cognitive impairment established on ART for at least 6 months with a suppressed viral load attending public sector ART clinics in Cape Town, South Africa. We excluded participants with an eGFR <60 mL/min and treated with medications predisposing to lithium toxicity. We reviewed participants weekly for the first month for adverse events followed by 4 weekly visits for renal function assessment, adverse event monitoring and adherence. Lithium dose was titrated to achieve the maintenance target plasma concentration of between 0.6 and 1.0 mmol/L. Sham lithium concentrations were generated for participants receiving placebo.ResultsWe included 23 participants allocated to the lithium arm and 30 participants allocated to the placebo arm. Baseline characteristics were not statistically different with a mean age of 37.7 and 40.8 years, a median time on ART of 33 and 40 months and an eGFR of 139.3 and 131.0 mL/min in the lithium and placebo arms respectively. There was no statistical significant difference in the reduction in eGFR or increase in potassium between the two arms during the 24 weeks.ConclusionsWe found that 24-week treatment of HIV-infected patients with lithium and TDF did not result in increased nephrotoxicity.Trial registration The study was registered on the Pan African Clinical Trials Registry (PACTR) with the identifier number PACTR201310000635418. Registered 11 October 2013 before the first participant was enrolled

Hyponatremia is a marker of disease severity in HIV-infected patients: a retrospective cohort study

BackgroundHyponatremia is a frequent electrolyte disorder in HIV-infected patients with a prevalence of up to 56% in the pre-cART era. Several studies have demonstrated that patients with hyponatremia are at an increased risk of death. We aimed to investigate the prevalence of hyponatremia in the recent cART-era and evaluate its association with mortality.MethodsSingle-center retrospective cohort study. A total of 1196 newly diagnosed and cART-naïve HIV patients followed at the AIDS Reference Center, St Pierre University Hospital in Brussels, Belgium, between 1 January 1998 and 31 December 2013 were included. Hyponatremia was defined as a baseline natremia lower than 135 mmol/l. The outcome of interest was the occurrence of death.ResultsIn this study 177 (14.8%) patients had hyponatremia at baseline with a median natremia of 132.0 mmol/l [interquartile range (IQR) 130.0-134.0 mmol/l]. Hyponatremic patients had a lower CD4 cell count (207.5 ± 197.7/μl vs 400.4 ± 277.0/μl; P < 0.0001) and a higher prevalence of AIDS (50.3% vs 12.4%; P < 0.0001) compared to normonatremic patients. A significantly higher proportion of patients with hyponatremia were hospitalized at first contact (72.3% vs 20.0%; P < 0.0001). During the follow-up hyponatremic patients had a shorter median time to a first hospitalization (2.0 IQR [0.0-12.0] months vs 13.0 IQR [2.0-29.0] months; P = 0.001) and an increased incident hospitalization rate (785/1000 patient-years, 95% CI 725–845 vs 370/1000 patient-years, 95% CI 352–388; P < 0.0001]. The incident mortality rate was 28.3/1000 patient-years (95% CI 18.15-42.16) in patients with hyponatremia compared to 9.33/1000 patient-years (95% CI 6.63-12.75) in normonatremic patients (P < 0.0001). Three-year cumulative survival rates were 85.8% ± 3.0% in hyponatremic patients and 96.3% ± 0.7% in normonatremic patients (log-rank P < 0.0001). However, in a multivariate Cox model adjusting for other risk factors such as AIDS, CD4 count < 350/μl and hepatitis C, hyponatremia was no longer a predictor for patient death (hazard ratio: 1.03, 95% CI 0.54-1.97; P = 0.935).ConclusionsHyponatremia is a marker of severity of HIV-disease but not an independent risk factor for mortality. HIV-patients with a low serum sodium at baseline might benefit from a close follow-up to improve outcomes.

Cognitive impairment and mental disorders in HIV-infected patients with early stages of syphilis

Cognitive impairment and mental disorders in HIV-infected patients with early stages of syphilis

Attention Deficit and Hyperactivity Disorder in HIV-Infected Patients

Attention Deficit and Hyperactivity Disorder in HIV-Infected Patients

The structure of mental disorders in HIV-infected patients with syphilis

IntroductionThere are no data in literature on mental disorders in HIV-infected patients with syphilis.The objective of the study was to determine the structure of mental disorders in HIV-infected patients with syphilis.MethodSixty-five HIV-infected patients with syphilis were examined by a clinical method.ResultsThe sample included 45 men (average age 32.09 ± 9.83) and 20 women (average age 31.7 ± 5.97). We divided the sample into three comparison groups (according to the importance of risk factors): women, men who have sex with men (MSM), and men who have sex with women (MSW).Mental disorders were identified in most patients (83%). Opiate dependence (F11, ICD-10) was established in 55% of women (7.7% for MSW, 0% in MSM; P &lt; 0.001). The dependence on multiple drug use (F19) was revealed with nearly the same frequency in women (25.0%) and in MSW (23.1%); but far less frequently in MSM (3.2%; P = 0.047). The dependence on stimulants (F15) was found in women (5.0%) and MSM (6.3%). The dependence on alcohol (F10) was more common among MSW (61.5%) and women (50.0%) (9.4% in MSM; P &lt; 0.001). 20% of women had Depressive episode (F32). Adjustment disorders (F43) were found much more often in men (43.8% for MSM; 38.5% for MSW; 10% for women; P = 0.035). Personality disorders (F60) were found in all the groups.ConclusionsWe revealed a high incidence of addictions among women and MSW. Affective disorders were represented by depressive episode in women and adjustment disorders in men.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Mental disorders in patients with HIV infection: systematics and features of development

To identify and systematize characteristics and patterns of formation and development of mental disorders in HIV-infection. Two hundred and fifty patients with HIV-infection and 50 injection drug users, aged 18-50 years, were examined. Most of HIV-infected people were aged from 21 to 40 years. In addition to clinical and psychopathological methods, clinical laboratory instrumentation and experimental psychological method were used. Mental disorders in HIV-infected patients include psychogenic-reactive, exogenous organic and personality disorders. The dynamics of these disorders depends on the combined effects of somatogenic, nosogenic and premorbid personality factors.

Clinical Usefulness of Brain Functional MRI for Diagnosing HIV-Associated Neurocognitive Disorder in HIV-Infected Patients

Author(s): Ann, Hea Won; Jeon, Yong Duk; Ahn, Jin Young; Ku, Nam Su; Kim, June Myung; Shin, Na-Young; Smith, Davey M; Choi, Jun Yong; Jun, Suhnyoung; Ahn, Mi-Young; Han, Sanghoon; Jung, In Young

Correlation between inflammatory biomarkers and metabolic disorders in HIV infected patients undergoing antiretroviral therapy

Correlation between inflammatory biomarkers and metabolic disorders in HIV infected patients undergoing antiretroviral therapy Raluca Mihailescu, Victoria Arama, Catalin Tiliscan, Daniela Munteanu, Viorica Leoveanu, Mihaela Radulescu, Adriana Hristea, Cristina Popescu, Ruxandra Moroti, Violeta Molagic, Raluca Nastase, Loredana Benea, Ana Maria Tudor, Mihai Lazar, Anca-Ruxandra Negru, Irina Lapadat, Ligia Ionescu, Mirela Cernat, Georgeta Juganaru, Doina Cristea, Adriana Manea, Adrian Streinu-Cercel, Daniela Adriana Ion, Sorin Ștefan Arama